Related Experiment Video
Updated: May 14, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Improved vancomycin dosing in children using area under the curve exposure
Jennifer Le1, John S Bradley, William Murray
1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093-0714, USA. jenle@ucsd.edu
Insights
Vancomycin dosing in children requires higher doses (60-70 mg/kg/day) to achieve therapeutic area under the curve/minimum inhibitory concentration (AUC/MIC) targets. Trough concentrations are less reliable for vancomycin efficacy in pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Clinical Pharmacy
Background:
- Vancomycin is a critical antibiotic for treating serious Gram-positive infections in children.
- Optimizing vancomycin dosing in pediatric populations is essential for effective treatment and minimizing resistance.
- Current dosing strategies may not consistently achieve therapeutic targets in children.
Purpose of the Study:
- To determine vancomycin pharmacokinetic indices in pediatric patients.
- To compare the attainment of two target exposures: AUC/MIC ≥400 and trough concentration ≥15 mcg/mL.
- To inform optimal vancomycin dosing regimens for children.
Main Methods:
- Population-based pharmacokinetic modeling using NONMEM 7.2.
- Analysis of vancomycin serum concentrations from 702 pediatric patients (≥3 months old).
- Monte Carlo simulations (N=11,000) to evaluate dosing regimens and target attainment.
Main Results:
- Developed pharmacokinetic models for vancomycin clearance and volume of distribution based on age, weight, and creatinine.
- Initial median vancomycin dose (44 mg/kg/day) was inadequate for most subjects.
- Doses of 60-70 mg/kg/day achieved target AUC/MIC in ~75% of simulated pediatric subjects.
Conclusions:
- Vancomycin area under the curve to minimum inhibitory concentration (AUC/MIC) is a more reliable target than trough concentrations in children.
- Higher vancomycin dosages (60-70 mg/kg/day) are necessary to achieve target AUC/MIC ≥400 in approximately 75% of pediatric patients.
- Individualized vancomycin dosing adjustments based on age, creatinine, and MIC are crucial for pediatric patients.
Background:
: Our objectives were to (1) determine the pharmacokinetic indices of vancomycin in pediatric patients; and (2) compare attainment of 2 target exposures: area under curve (AUC) / minimum inhibitory concentration (MIC) ≥400 and trough concentration ≥15 mcg/mL.
Methods:
: The population-based pharmacokinetic modeling was performed using NONMEM 7.2 for children ≥3 months old who received vancomycin for ≥48 hours from 2003 to 2011. A 1-compartment model with first-order kinetics was used to estimate clearance, volume of distribution and AUC. Empiric Bayesian post hoc individual parameters and Monte Carlo simulations (N = 11,000) were performed.
Results:
: Analysis included 702 patients with 1660 vancomycin serum concentrations. Median age was 6.6 (interquartile range 2.2-13.4) years, weight 22.7 (12.6-46) kg and baseline serum creatinine 0.40 (0.30-0.60) mg/dL. Final model pharmacokinetic indices were clearance (L/h) = 0.248 * Wt * (0.48/serum creatinine) * (ln(age)/7.8) and volume of distribution (L) = 0.636 * Wt. Using these parameters and the observed MIC distribution, Monte Carlo simulation indicated that the initial median dose of 44 (39-52) mg/kg/day was inadequate in most subjects. Regimens of 60 mg/kg/day for subjects ≥12 years old and 70 mg/kg/day for those <12 years old achieved target AUC/MIC in ~75% and trough concentrations ≥15 in ~45% of virtual subjects. An AUC/MIC ~400 corresponded to trough concentration ~8 to 9 mcg/mL.
Conclusions:
: Targeted exposure using vancomycin AUC/MIC, compared with trough concentrations, is a more realistic target in children. Depending on age, serum creatinine and MIC distribution, vancomycin in a dosage of 60 to 70 mg/kg/day was necessary to achieve AUC/MIC ≥ 400 in 75% of patients.
More Related Videos
08:24Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Estimation of k and VD of Aminoglycosides